Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — Investor Presentation (September 2023)
29 slides from Xbrane Biopharma AB's investor presentation, September 2023
Slide 1: Xbrane – a World-Leading Biosimilar Developer
STO: XBRANE September 2023 Xbrane – a World-Leading Biosimilar Developer 1
Slide 2: Important information
Important information You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in
Slide 3: Xbrane addresses global health challenges by developing affordable biosimilars
Xbrane addresses global health challenges by developing affordable biosimilars Core competence Differentiation Develop biosimilars from Patented platform technology for cell line to market approval and lowest production cost partner for sales and marketing Our purpose: Mid-term strategic focus “Enab
Slide 4: Xbrane – a world-leading biosimilar developer
Xbrane – a world-leading biosimilar developer Biosimilars – a → Biosimilar market to grow to USD 74bn by 2030 as blockbuster biologic patents expire rapidly growing market → Delivering value to society - increased accessibility and significant savings → Unique, proprietary high-yield/low-cost platfo
Slide 5: Biosimilars – a rapidly growing market
Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 50bn in originator sales
Slide 6: Biosimilars are follow-on products to biologics launched post patent expiry
Biosimilars are follow-on products to biologics launched post patent expiry Pharmaceuticals Small Molecules Biologics → 60% of global market, 1-3% p.a. growth1 → 40% of global market, 10-15% p.a. growth2 → Produced via chemical synthesis → Produced via recombinant DNA technology → Followed on by ide
Slide 7: Biosimilar development – faster, cost-effective & low risk
Biosimilar development – faster, cost-effective & low risk Pre-clinical Phase I Phase III Biosimilar Likelihood of Approval1 78% 95% development process Development time Capital requirement Prob. of success Cost effectiveness 7 years +€100 million MEDIUM - HIGH Improved patient access Discovery & De
Slide 8: Biosimilars rapidly claim majority of reference product market share
Biosimilars rapidly claim majority of reference product market share Rapid biosimilars uptake leading to USD 11.5bn in global sales (2021) Favorable margins & price discounts Branded products WW annual sales Biosimilars WW annual sales → Biosimilars have in recent launches taken +70% USD million USD
Slide 9: Biosimilar market expected to grow to USD 74bn by 2030
Biosimilar market expected to grow to USD 74bn by 2030 Biologics with >USD 260bn in sales lose exclusivity by 2032 Biosimilar market to grow by 17% per year through to 2030 Estimated cumulative global annual peak sales, USD billion Global biosimilar sales, USD billion 74.0 61.5 54.5 51.6 35.4 32.9 1
Slide 10: Xbrane – a platform biosimilar developer
Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 50bn in originator sales 10
Slide 11: Xbrane´s modular platform technology enables significant yield advantage
Xbrane´s modular platform technology enables significant yield advantage Proprietary host cell line library Productivity enhancing technologies Process and analytical methods + + → Library of proprietary genetically → Productivity and quality enhancing → Specific production process methods engineere
Slide 12: Diverse development portfolio addressing a €53bn market
Diverse development portfolio addressing a €53bn market Originator peak sales estimate 2026* (€ billion) Biosimilar Ximluci® BIIB801™ Xdivane™ Xtrudane™ Xdarzane™ Current portfolio candidate Branded biologics Therapeuti Ophthalmology Immunology Oncology Oncology Oncology c area Patent 2020 (US) 2024
Slide 13: World-leading partnerships secured with >€80m in upcoming milestones
World-leading partnerships secured with >€80m in upcoming milestones Product Ximluci® BIIB801TM Commercial Partner Territory Global ex. China Global Type Co-development License Upfront €7.5m USD 8m > €80m (pending) Milestones / Cost coverage €40-50m USD 80m Royalties/ profit sharing 50% EBITDA profi
Slide 14: Ximluci® – ongoing commercialisation in Europe & UK
Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 50bn in originator sales 14
Slide 15: Ximluci® – addressing a global underserved market
Ximluci® – addressing a global underserved market Lucentis® used in treatment of severe eye diseases Global unmet medical need due to high drug cost 5 million affected eyes Europe & US, 50% treated Affected vision Normal vision Untreated Lucentis Eylea Avastin 0.6 2.5 2.5 1.1 0.8 13 million affected
Slide 16: Ximluci® commercialisation – geographical expansion underway
Ximluci® commercialisation – geographical expansion underway 2022 2023 2024 Regulatory process EU Production launch volume* Regulatory process US Drug substance process scale-up Pre-filled syringe development June 2023 Q2 2024 Q1 2025 Feb 2022 July 2022 March 2023 Q2 2024 FDA accepts Expected US Exp
Slide 17: Ximluci® launched across 35-40% of € 5 billion ex-US market
Ximluci® launched across 35-40% of € 5 billion ex-US market Retinal anti-VEGF sales (ex US) Comments € million Approx. € 200-300m / quarter additional market from off label Avastin1 → Ex-US market for retinal anti-VEGFs approx. € 5 billion annually → Ximluci® launched by partner STADA in approx. 35-
Slide 18: Xbrane generated revenues of SEK 85 million from Ximluci H1 2023
Xbrane generated revenues of SEK 85 million from Ximluci ® H1 2023 Xbrane sell Finished Goods to STADA… …and gets 50% of profits generated from in market sales Xbrane sales of finished goods to STADA (MSEK) Ximluci net-sales (SEK million) ILLUSTRATIVE Q1 '23 Q2 '23 Ximluci sales growth Q2 vs Q1 50.0
Slide 19: Ximluci® BLA submitted to FDA with BsUFA date in April 2024
Ximluci® BLA submitted to FDA with BsUFA date in April 2024 Retinal anti-VEGF sales (US) Comments € million Approx. USD 150m / quarter additional annual market from off label Avastin1 → US market for retinal anti-VEGFs approx. $8 billion annually → Ongoing out-licensing of Ximluci North America comm
Slide 20: Attractive portfolio addressing USD 50bn in originator sales
Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 50bn in originator sales 20
Slide 21: Cimzia® is a differentiated €2.1 billion TNFa inhibitor
Cimzia® is a differentiated €2.1 billion TNFa inhibitor Cimzia® is a differentiated TNFa inhibitor Cimzia® generated €1.8 billion in sales 2021 Cimzia® sales (€ millions) Rheumatoid Arthritis (RA) Psoriasis 2500 2000 1500 1000 500 → Cimzia® is a TNFa inhibitor that reduce immune response in auto-imm
Slide 22: BIIB801™ – the only publicly known Cimzia® biosimilar under development
BIIB801™ – the only publicly known Cimzia® biosimilar under development BIIB801™ programme Partnership with Biogen with attractive terms → Out-licensing of global rights → Pilot scale process established → Xbrane responsible for and fund pre-clinical → Ongoing tech-transfer/scale-up to selected drug
Slide 23: Well-positioned & commercially attractive oncology biosimilar portfolio
Well-positioned & commercially attractive oncology biosimilar portfolio Opportunity to make a difference Oncology biosimilar portfolio €48 billion of annual reference product sales Originator Combined annual expected peak → Annual per patient cost of reference product sales >USD 100K 2028 (US) Xdiva
Slide 24: Upcoming key milestones
Upcoming key milestones Ximluci® out-licensing of North American rights Ximluci® FDA approval and launch BIIB801 scale up of production process and production of clinical material triggering milestone payments as per agreement with Biogen XdivaneTM out-licensing Reaching positive operating
Slide 25: Xbrane – a world-leading biosimilar developer
Xbrane – a world-leading biosimilar developer Biosimilars – a → Biosimilar market to grow to USD 74bn by 2030 as blockbuster biologic patents expire rapidly growing market → Delivering value to society - increased accessibility and significant savings → Unique, proprietary high-yield/low-cost platfo
Slide 26: Appendix
Xbrane – a world-leading biosimilar developer Appendix 26
Slide 27: Experienced management team and board
Experienced management team and board Management Board of Directors Martin Åmark Siavash Bashiri David Vikström Anders Wallström Anders Tullgren Eva Nilsagård Karin Wingstrand Mats Thorén CEO COO & Head of CTO Head of Manufacturing Chairman of the Director of the Director of the Director of the Bios
Slide 28: Latest financials & shareholder list
Latest financials & shareholder list Shareholder list (31 August 2023) Financial highlights Investor Name Shares Ownership, % SEK thousands H1 2023 H1 2022 Serendipity Group 3,175,673 10.9 Bengt Göran Westman 2,294,604 7.9 Revenue 112,945 26,204 Nordnet Pensionsförsäkring 1,646,928 5.6 STADA Arzneim
Slide 29: Xbrane – a World-Leading Biosimilar Developer
STO: XBRANE Xbrane – a World-Leading Biosimilar Developer 29
Xbrane Biopharma — Investor Presentation (September 2023) on 6ix